New Zealand King Salmon Investments (NZK)•HY26•Released 26 May 2026Profit swing to NZ$13.8m masks operating cash flow halving to NZ$7.3mPre-lease FCF turned negative at NZ$5.0m as capex rose and debtors built, even with biological performance lifting EBITDA to NZ$24.0m.Published 26 May 2026Read briefing→
New Zealand King Salmon Investments (NZK)•HY26•Released 25 September 2025NPAT swung to a $20.8m loss on a $31.2m biological asset write-downOperating cash flow rose 21.2% to $19.6m, but volumes fell 17% and FY26 pro-forma EBITDA guidance of just $1-7m points to genuine operating pressure.Published 23 April 2026Read briefing→
New Zealand King Salmon Investments (NZK)•FY25•Released 27 March 2025Revenue up 12.8% but NPAT fell 53% on biological-asset fair value swingHeadline NPAT fell on a $7.7m fair-value loss on biological assets versus a $15.8m prior gain, while operating cash flow nearly tripled to $38.5m.Published 23 April 2026Read briefing→
New Zealand King Salmon Investments (NZK)•HY25•Released 24 September 2024NPAT fell 43% but pro-forma EBITDA rose to $13.5m on biological-asset swingA $7.7m non-cash biological-asset/inventory swing pulled GAAP earnings down even as volumes, revenue and the company's guided pro-forma measurePublished 23 April 2026Read briefing→
New Zealand King Salmon Investments (NZK)•FY24•Released 27 March 2024NZK FY24: $24.5m pro-forma EBITDA hit, but $1.4m H2 cash exposes quality gapReported NPAT of $28.5m is flattered by a $15.8m fair value uplift and cash conversion ran at just 28.1% as working capital absorbed $12.3m.Published 22 April 2026Read briefing→
New Zealand King Salmon Investments (NZK)•HY24•Released 21 September 2023NZK swung to $10.6m profit and lifted EBITDA guidance to $23.5-27.5mRecovery from the FY23 mortality event delivered a $36.4m EBITDA swing, but reported EBITDA of $18.5m sits well above pro-forma EBITDA of $10.7m.Published 22 April 2026Read briefing→